Travere Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
All right. Good morning, everyone. My name is Do Kim. I'm one of the biotech analysts here at Piper. Next up, we have Travere. It is my pleasure to welcome CFO, Chris Cline.
Maybe we could start, Chris, just with you providing a brief introduction to the company and the key milestones that we are looking forward to.
Yeah. That's great. First off, thanks, Do, and thanks to Piper for having us today. It's great to be here.
I will be making forward-looking statements. So for a full risk factors and disclosures, please see our SEC filings.
But as many of you know, at Travere, we are exclusively focused on delivering life-changing therapies to people living with rare disease, and really coming into a very exciting time for the company. And really that's led by the fact that we're preparing for multiple launches from our pipeline.
And the first of those is sparsentan for IGA nephropathy, and we're preparing for a PDUFA date coming up in February of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |